Liposomal amphotericin B for treatment of acute phase and secondary prophylaxis of visceral leishmaniasis in a HIV positive patient;Utilizzo dell'amfotericina B liposomiale nel trattamento della fase acuta e nella profilassi secondaria della leishmaniosi viscerale in un paziente HIV positivo

Infezioni in Medicina

Volumn 8, Issue 4, 2000, Pages 241-244

  Murdaca, G ^a   Setti, M ^a   Campelli, A ^a   Ghio, M ^a   Puppo, F ^a   Indiveri, F ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Amphotericin B; HIV; Visceral Leishmaniasis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; DIAMORPHINE;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CLINICAL TRIAL; DYSPHONIA; FEVER; GIEMSA STAIN; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERTROPHY; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; LARYNGOSCOPY; LEISHMANIA INFANTUM; MALE; RECURRENT DISEASE; REMISSION; VISCERAL LEISHMANIASIS; VOCAL CORD; WEIGHT REDUCTION;

EID: 0034528305     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Visceral Leishmaniasis: An opportunistic infection in AIDS
2. Epidemiological surveillance of leishmaniasis in HIV-infected individuals in Italy
3. Kala-azar comes to New York
4. Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas non endemic for Leishmania donovani
5. Leishmania Species: Visceral (Kala-azar), cutaneous, and mucosal leishmaniasis
6. Leishmania and human immunodeficiency virus coinfection: The first 10 years
7. Visceral Leishmaniasis in patients with HIV infection
8. Immunological findings in HIV-Leishmania coinfection
9. Visceral Leishmaniasis and HIV- 1 coinfection in southern France
10. Visceral Leishmaniasis in HIV infected patients: Treatment with high dose liposomal amphotericin B (Ambisome)
11. The clinical and evolutional characteristics of visceral leishmaniasis in patients with HIV infection
12. Leishmaniasis
13. The compromised traveler
14. Leishmaniasis and ENT
15. Laryngeal leishmaniasis as initial opportunistic disease in HIV infection
16. Two cases of laryngeal leishmaniasis in patients infected with HIV
17. Isolated laryngeal leishmaniasis in an immunocompetent patient: Successful treatment with surgery
18. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients
19. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus
20. Liposomal amphotericin B (Ambisome) in Mediterranean visceral Leishmaniasis: A multi-centre trial
21. Liposomal amphotericin B. Therapeutic use in the management of fungal infection and visceral leishmaniasis
22. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies
23. An EORTC international multicenter randomized trial (EORTC Number 19923) comparing two dosages of liposomal Amphotericin B for treatment of invasive aspergillosis